• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

移植后血液或骨髓的条件强度和活产概率,BMTSS 报告。

Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report.

机构信息

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Department of Population Sciences and Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; and.

出版信息

Blood Adv. 2022 Apr 26;6(8):2471-2479. doi: 10.1182/bloodadvances.2021006300.

DOI:10.1182/bloodadvances.2021006300
PMID:34933332
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9043940/
Abstract

We examine the impact of conditioning intensity (low intensity: nonmyeloablative/reduced intensity vs high intensity: myeloablative) and total body irradiation (TBI) on the probability of live birth after blood or marrow transplantation (BMT). Study participants were drawn from the BMT Survivor Study (BMTSS) and included 1607 transplant survivors between 1974 and 2014 at age ≤45 years, with survival ≥2 years post-BMT and age at study ≥18 years. Closest-age, same-sex biologic siblings (n = 172) were 1:1 matched with 172 survivors. Survivors and siblings self-reported information on sociodemographic, chronic health conditions, and pregnancies. Within survivor analysis: the association between the primary exposure variable (no TBI/low-intensity conditioning; 200 to 800 cGy TBI/low-intensity conditioning; no TBI/high-intensity conditioning; >800 cGy TBI/high-intensity conditioning) and the odds of no post-BMT live birth were examined using multivariable logistic regression, adjusting for clinical and demographic variables. Median age at BMT was 31 years (IQR, 0 to 45), and median length of follow-up was 14.3 years (IQR, 2.4 to 41.4); 39.3% were autologous BMT recipients, and 46.6% were female. Overall, 120 (8.7%) survivors reported post-BMT live births. Receipt of >800 cGy TBI/high-intensity conditioning (odds ratio [OR], 3.7; 95% CI, 1.9-7.0; ref: no TBI/low-intensity conditioning) was associated with higher odds of reporting no live birth post-BMT. In contrast, 200 to 800 cGy TBI/low-intensity conditioning (OR, 1.3; 95% CI, 0.5-3.3), and no TBI/high-intensity conditioning (OR, 0.9; 95% CI, 0.5-1.7) were at similar risk of reporting post-BMT live birth as no TBI/low-intensity conditioning. Comparison with biologic siblings: Using conditional logistic regression, we found that BMT survivors were more likely to report no live birth (OR, 2.0; 95% CI, 1.2-3.3) compared with siblings. These findings could inform conditioning intensity options for patients wishing to preserve fertility post-BMT.

摘要

我们研究了预处理强度(低强度:非清髓性/减强度与高强度:清髓性)和全身照射(TBI)对≤45 岁年龄的血液或骨髓移植(BMT)后活产概率的影响。研究参与者来自 BMT 幸存者研究(BMTSS),包括 1974 年至 2014 年间生存≥2 年的 1607 名 BMT 幸存者,且研究时年龄≥18 岁。年龄最接近的同性别生物同胞(n=172)按 1:1 与 172 名幸存者匹配。幸存者和同胞自我报告社会人口统计学、慢性健康状况和妊娠信息。在幸存者分析中:使用多变量逻辑回归,调整临床和人口统计学变量,研究主要暴露变量(无 TBI/低强度预处理;200 至 800cGyTBI/低强度预处理;无 TBI/高强度预处理;>800cGyTBI/高强度预处理)与无 BMT 后活产的几率之间的关联。BMT 的中位年龄为 31 岁(IQR,0 至 45),中位随访时间为 14.3 年(IQR,2.4 至 41.4);39.3%为自体 BMT 受者,46.6%为女性。总体而言,120 名(8.7%)幸存者报告了 BMT 后活产。接受>800cGyTBI/高强度预处理(比值比[OR],3.7;95%CI,1.9-7.0;参考:无 TBI/低强度预处理)与 BMT 后报告无活产的几率较高相关。相比之下,200 至 800cGyTBI/低强度预处理(OR,1.3;95%CI,0.5-3.3)和无 TBI/高强度预处理(OR,0.9;95%CI,0.5-1.7)与无 TBI/低强度预处理的报告 BMT 后活产的风险相似。与生物同胞的比较:使用条件逻辑回归,我们发现与同胞相比,BMT 幸存者更有可能报告无活产(OR,2.0;95%CI,1.2-3.3)。这些发现可以为希望在 BMT 后保留生育能力的患者提供预处理强度选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/22140897c992/advancesADV2021006300f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/75a5b4e62cb2/advancesADV2021006300absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/fda2fd631b6e/advancesADV2021006300f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/d6c42659cab1/advancesADV2021006300f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/22140897c992/advancesADV2021006300f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/75a5b4e62cb2/advancesADV2021006300absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/fda2fd631b6e/advancesADV2021006300f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/d6c42659cab1/advancesADV2021006300f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eea/9043940/22140897c992/advancesADV2021006300f3.jpg

相似文献

1
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report.移植后血液或骨髓的条件强度和活产概率,BMTSS 报告。
Blood Adv. 2022 Apr 26;6(8):2471-2479. doi: 10.1182/bloodadvances.2021006300.
2
Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report.全身照射与血液或骨髓移植后乳腺癌风险:血液或骨髓移植幸存者研究报告。
J Clin Oncol. 2020 Sep 1;38(25):2872-2882. doi: 10.1200/JCO.20.00231. Epub 2020 Jul 16.
3
Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model.异基因血液或骨髓移植幸存者中迟发性静脉血栓栓塞症:BMTSS-HiGHS2 风险模型。
Blood Adv. 2021 Oct 26;5(20):4102-4111. doi: 10.1182/bloodadvances.2021004341.
4
Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report.遗传性代谢病异基因造血或骨髓移植后发病率负担:BMT 幸存者研究报告。
Transplant Cell Ther. 2022 Mar;28(3):157.e1-157.e9. doi: 10.1016/j.jtct.2021.11.023. Epub 2021 Dec 5.
5
Pre-frailty after blood or marrow transplantation and the risk of subsequent mortality.移植术后的虚弱前期与随后的死亡风险。
Leukemia. 2024 Jul;38(7):1592-1599. doi: 10.1038/s41375-024-02238-2. Epub 2024 Apr 5.
6
Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report.COVID-19 感染风险在血液或骨髓移植长期幸存者中的研究:BMTSS 报告。
Blood Adv. 2023 Jun 27;7(12):2843-2854. doi: 10.1182/bloodadvances.2022009550.
7
Health care utilization by long-term survivors of blood or marrow transplantation-A Bone Marrow Transplant Survivor Study report.血液或骨髓移植长期幸存者的医疗保健利用情况——一份骨髓移植幸存者研究报告。
Cancer. 2024 Mar 1;130(5):803-815. doi: 10.1002/cncr.35076. Epub 2023 Oct 25.
8
Pain in older survivors of hematologic malignancies after blood or marrow transplantation: A BMTSS report.血液或骨髓移植后老年血液恶性肿瘤幸存者的疼痛:BMTSS 报告。
Cancer. 2020 Jan 1;126(9):2003-2012. doi: 10.1002/cncr.32736. Epub 2020 Feb 5.
9
Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.自体血液或骨髓移植幸存者中的静脉血栓栓塞症:来自血液或骨髓移植幸存者研究的报告。
Biol Blood Marrow Transplant. 2019 Nov;25(11):2261-2266. doi: 10.1016/j.bbmt.2019.06.032. Epub 2019 Jul 3.
10
Nonmyeloablative conditioning regimens and bone marrow transplantation--some contemporary aspects.非清髓性预处理方案与骨髓移植——一些当代观点
Folia Med (Plovdiv). 2010 Jan-Mar;52(1):12-7.

引用本文的文献

1
Women's Sexual Dysfunctions Following Stem Cell Transplant and the Impact on Couple Relationship.干细胞移植后女性的性功能障碍及其对夫妻关系的影响。
Life (Basel). 2023 Dec 25;14(1):35. doi: 10.3390/life14010035.
2
Successful testicular sperm extraction after hematopoietic stem cell transplantation.造血干细胞移植后成功进行睾丸精子提取。
Asian J Androl. 2023;25(4):539-540. doi: 10.4103/aja202294.

本文引用的文献

1
Sexuality- and Fertility-Related Issues in Women after Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后女性的性生活和生育相关问题。
Transplant Cell Ther. 2021 May;27(5):432.e1-432.e6. doi: 10.1016/j.jtct.2021.02.003. Epub 2021 Feb 6.
2
Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.造血细胞移植后的卵巢功能:一项关于在清髓性预处理中使用促性腺激素释放激素激动剂以及在减低强度预处理中仅进行观察的描述性研究。
Bone Marrow Transplant. 2016 Oct;51(10):1369-1375. doi: 10.1038/bmt.2016.150. Epub 2016 Jun 6.
3
Childhood to adult transition and long-term follow-up after blood and marrow transplantation.
血液和骨髓移植后的儿童期至成人期过渡及长期随访
Bone Marrow Transplant. 2016 Feb;51(2):176-81. doi: 10.1038/bmt.2015.228. Epub 2015 Dec 7.
4
Prevalence of hematopoietic cell transplant survivors in the United States.美国造血细胞移植幸存者的患病率。
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501. doi: 10.1016/j.bbmt.2013.07.020. Epub 2013 Jul 30.
5
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.在异体造血细胞移植使用率显著增加、受体年龄较大以及使用非亲缘供体的情况下,患者的生存率得到了显著提高。
J Clin Oncol. 2013 Jul 1;31(19):2437-49. doi: 10.1200/JCO.2012.46.6193. Epub 2013 May 28.
6
Positive reproductive family history for spontaneous abortion: predictor for recurrent miscarriage in young couples.有自然流产史的阳性生殖家族史:年轻夫妇复发性流产的预测因素。
Eur J Obstet Gynecol Reprod Biol. 2012 Apr;161(2):182-6. doi: 10.1016/j.ejogrb.2011.12.027. Epub 2012 Jan 26.
7
Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?降低异基因造血细胞移植后移植相关死亡率的风险:取得了多大进展?
J Clin Oncol. 2011 Mar 1;29(7):805-13. doi: 10.1200/JCO.2010.32.5001. Epub 2011 Jan 10.
8
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).造血细胞移植后妊娠:来自国际血液和骨髓移植研究中心(CIBMTR)晚期效应工作组的报告。
Biol Blood Marrow Transplant. 2011 Feb;17(2):157-66. doi: 10.1016/j.bbmt.2010.07.009. Epub 2010 Jul 24.
9
Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study.造血细胞移植后的受孕率及妊娠结局:来自骨髓移植幸存者研究的报告。
Bone Marrow Transplant. 2006 Jun;37(11):1023-9. doi: 10.1038/sj.bmt.1705364.
10
Fertility preservation and pregnancy outcome after malignancy.恶性肿瘤后的生育力保存及妊娠结局
Curr Opin Obstet Gynecol. 2005 Feb;17(1):21-6. doi: 10.1097/00001703-200502000-00005.